<?xml version="1.0" encoding="UTF-8"?>
<p id="par0125">Ribavirin that binds to the active site on RdRp has been used for years as components of treatment for hepatitis C [
 <xref rid="bib0275" ref-type="bibr">55</xref>], has broad-spectrum activities against viruses including MERS-CoV, SARS-CoV-2 [
 <xref rid="bib0255" ref-type="bibr">51</xref>,
 <xref rid="bib0260" ref-type="bibr">52</xref>]; it can influence the dosage of anticoagulants and can also influence the activity of P2Y12 inhibitors through the inhibition of CYP3A4, which results in a reduction of the serum concentrations of the active metabolites of and increased serum concentrations [
 <xref rid="bib0280" ref-type="bibr">56</xref>].
</p>
